We observed that MRX34 treatment increased miR-34a levels in tumors and concurrently downregulated tumor PDL1 mRNA and PDL1 protein as measured by quantitative real-time polymerase chain reaction and western blotting (Figure 4, A-C). The gene discussed is IL1RAPL1; the disease is neoplasm.